Bioanalysis and Biotransformation in Drug Discovery and Development
Guildford, UK, and Burlington, Mass., January 26, 2011 – IDBS, the leading worldwide provider of data management and analytics solutions to R&D and healthcare organizations, today announced it will present ‘Acclerating Bioanalytical Report Generation with Quality Control in Real Time’, at the Applied Pharmaceutical Analysis (APA) India conference February 6 – 9, 2011 in Hyderabad, India. The event will focus on bioanalysis and biotransformation in the drug discovery and development process, looking both at current practices as well as future trends.
All bioanalytical laboratories strive to provide quality data quickly, and performing quality control (QC) checks on data and laboratory procedures is one way to assure sufficient quality. Traditionally, QC is performed after data has been acquired, meaning that errors are identified and addressed after they occur. At this point, issues can be resolved only by resource-intensive investigative processes and/or by re-work, both of which have a negative impact on the bioanalysis laboratory’s productivity and efficiency.
In his session, which is part of the Regulated Bioanalysis track, Dr. Joe Rajarao, Senior Consultant, IDBS will discuss the use of an electronic lab notebook (ELN) solution to support common bioanalytical laboratory workflows and provide an audit-tracked and paperless environment as well as automatically detect deviations from the approved method and alert the user to potentially auditable findings.
The 2011 conference will be held February 6-9 at the Hotel Novotel Hyderabad International Conference Center, Hyderabad, India. IDBS will present on Wednesday, February 9, at 3:15 pm. For more information on the conference or to register visit bostonsociety.org/APA-India.
IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist’s bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards.
Founded in 1989 and headquartered in Guildford, UK, IDBS has worldwide consulting and support presence, with offices in California, New Jersey and Massachusetts, as well as in the EU, Australia and China. IDBS is a 2010 Profit Track 100 company.